FilingReader Intelligence
Glencore launches anti-fungal injection in US market
August 19, 2025 at 04:29 AM UTC•By FilingReader AI
Glencore Pharmaceuticals Inc., USA will launch Micafungin for Injection in September 2025, offering 50mg and 100mg single-dose vials.
The product is bioequivalent to Mycamine for Injection, which achieved annual sales of approximately $60.7m for the 12-month period ending June 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:GLENMARK•Bombay Stock Exchange
News Alerts
Get instant email alerts when Glenmark Pharmaceuticals publishes news
Free account required • Unsubscribe anytime